On August 21, 2023, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen Biotech") announced that it has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its Class 1 innovative therapeutic biological product SG1827 for injection. The indication is for the treatment of advanced malignant solid tumors.
One of the main mechanisms of action for SG1827 is to provide co-stimulatory signals for T cell activation. This plays a crucial role in promoting the recognition of and attack to tumors by immune cells, and it helps improve the clinical efficacy of immunotherapies such as anti-PD-1/PD-L1 antibody treatment. Early research has shown that SG1827, both as a monotherapy and in combination with other immune checkpoint antibodies, exhibits significant anti-tumor activity. Furthermore, no obvious cytokine release reactions have been observed, indicating good safety profiles.
Dr. Ming Lv, founder of Sumgen Biotech, stated: "SG1827 is one of Sumgen Biotech's most important pipeline layouts in the 'post-PD-1 era,' and is the company's ninth project to enter the clinical phase. SG1827 has a clear pharmacological mechanism, definite efficacy, and good safety. In the early stages of R&D, targeted molecular design was used to significantly optimize its PK characteristics and improve the developability. This not only puts SG1827 in a leading position in the global R&D competition for the same target but also gives it the potential to become a "Best in Class" drug. We will actively advance the clinical development of SG1827, striving to benefit more cancer patients as soon as possible."
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
